Advances and controversies in the management of soft tissue sarcomas. - sprookjes - yvandenbroek - TriplyDB

Advances and controversies in the management of soft tissue sarcomas.

Advances and controversies in the management of soft tissue sarcomas.

http://www.wikidata.org/entity/Q30240228

about

TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC.A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy.

P2860

Q46343999-3EF01C75-D8E0-4228-8885-84EF21C675D0 Q52682468-2BA0F4FB-C46B-478A-8774-EEFBACCEDD12

P2860

Advances and controversies in the management of soft tissue sarcomas.

http://www.wikidata.org/entity/Q30240228

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Advances and controversies in the management of soft tissue sarcomas.

@ast

Advances and controversies in the management of soft tissue sarcomas.

@en

type

label

Advances and controversies in the management of soft tissue sarcomas.

@ast

Advances and controversies in the management of soft tissue sarcomas.

@en

prefLabel

Advances and controversies in the management of soft tissue sarcomas.

@ast

Advances and controversies in the management of soft tissue sarcomas.

@en

P1433

Q30240228-636F0105-7B8B-46AB-B498-7110111DE0BC

P1476

Q30240228-5C053472-7B23-48F5-9E07-598640A92070

P2093

Q30240228-3611D066-50E1-4145-9FA5-9FCCC5CCF085

P2860

Q30240228-048F6615-C0F7-480E-944D-8126CE554CD8

Q30240228-05781694-811B-4716-A391-8EAF0878F532

Q30240228-07F54296-03F5-4197-B493-1E68E4E29088

Q30240228-0B8A7A89-894A-4ED9-8396-D8BBE0562397

Q30240228-30C39E23-F2EB-4316-BB9B-1698D01C98B0

Q30240228-421937AA-DF48-4531-94E5-7972CC8EA57A

Q30240228-42BC4784-7B7D-49CD-9ABB-3D42818969B5

Q30240228-4EF50159-E64B-4C34-8F80-67546C1D66BB

Q30240228-5E45E931-08FC-4F10-BC1D-488E224BDD10

Q30240228-692B62E6-ED12-4329-A4D5-C8CE4FD7F9C8

P304

Q30240228-220C192B-C814-45C5-8ADD-891D7D24855F

P31

Q30240228-C2CE07EB-DDAD-402F-AA51-12716573393E

P356

Q30240228-A9DE1CDD-08A9-4942-91C1-69D454345EAE

P407

Q30240228-AD8DA81D-BCB4-40AA-8F7B-808D280C77DB

P433

Q30240228-39095889-79E1-40F6-A7AC-DB3D4D877994

P478

Q30240228-C93C61BA-2A66-4543-B647-2D60B92AE237

P50

Q30240228-00DE5ABC-8A05-4D56-A1BA-A9D8C90912CF

Q30240228-90FBF2D0-7F60-4060-9572-515ED88A905C

P577

Q30240228-78B836D3-4D81-4F85-8ED5-810178DA9968

P698

Q30240228-B70BCE86-10F1-45C2-A044-F1AB47AD9B41

P356

P1433

Future Oncology

P1476

Advances and controversies in the management of soft tissue sarcomas.

@en

P2093

George D Demetri

http://www.w3.org/2001/XMLSchema#string

P2860

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

P304

3-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0498

http://www.w3.org/2001/XMLSchema#string

P407

P433

1s

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Giovanni Casali

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27918199

http://www.w3.org/2001/XMLSchema#string